Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinically definite diagnosis of NF1 according to the NIH consensus conference criteria.~2. Patients must have PN that have the potential to cause significant morbidity, such as lesions that could compromise the airway or the great vessels, lesions that could cause nerve compression, lesions that could result in major deformity or significant cosmetic problems~3. Measurable disease: patient must have at least one measurable PN amenable to volumetric MRI analysis.~Exclusion Criteria:~1. Chronic treatment with systemic steroids or another immunosuppressive agent.~2. Evidence of an active optic glioma, malignant glioma, malignant peripheral nerve sheath tumor, or other cancer requiring treatment with chemotherapy or radiation therapy.~3. Clinical evidence of significantly impaired lung function~4. Pregnancy or breast feeding.~5. Prior therapy with mTOR inhibitors (e.g.sirolimus, temsirolimus, everolimus).~6. No contraindications for MRI assessments~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Everolimus (RAD001) (Type: EXPERIMENTAL): enrolled patients received everolimus (RAD001) in an open label manner. Recommended starting dose of everolimus depend on body surface area, starting from 2.5 mg once daily to 7.5 mg once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).